Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of early propranolol administration on mortality from severe, traumatic brain injury: a retrospective propensity score-matched registry study.
Eur J Trauma Emerg Surg
January 2025
Department of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, 17033, USA.
Background: The role of beta-blockers in severe, traumatic brain injury (TBI) management is debated. Severe TBI may elicit a surge of catecholamines, which has been associated with increased morbidity and mortality. We hypothesize administering propranolol, a non-selective beta-blocker, within 48 h of TBI will reduce patient mortality within 30 days of injury.
View Article and Find Full Text PDFOur Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation.
Adv Ther
January 2025
Department of Dermatology, Rambam Health Care Campus, 8th Ha'aliya Hashnia, 3109601, Haifa, Israel.
Article Synopsis
- - Infantile hemangioma (IH) is a common benign tumor in infants that typically resolves on its own, but some cases require treatment with propranolol, which has a high success rate but may lead to rebound growth when stopped.
- - A study of 552 patients found that 12.6% experienced rebound growth after discontinuing propranolol; limb involvement predicted a lower likelihood of rebound growth, while younger age and a specific dose of 2 mg/kg/day improved treatment responses.
- - The research concluded that IHs on limbs displayed reduced rebound growth and better responses to propranolol, highlighting the importance of early treatment initiation and appropriate dosing for better outcomes.
Crowdsourcing Adverse Events Associated With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide Signaling for Migraine Prevention: Natural Language Processing Analysis of Social Media.
JMIR Form Res
November 2024
Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Clinical trials demonstrate the efficacy and tolerability of medications targeting calcitonin gene-related peptide (CGRP) signaling for migraine prevention. However, these trials may not accurately reflect the real-world experiences of more diverse and heterogeneous patient populations, who often have higher disease burden and more comorbidities. Therefore, postmarketing safety surveillance is warranted.
View Article and Find Full Text PDFEffective Treatment of Refractory Cluster Headache With Propranolol.
Cureus
September 2024
Department of Medicine and Surgery, College of Medicine, Umm Al-Qura University, Makkah, SAU.
Article Synopsis
- Cluster headache (CH) is a severe neurological condition causing intense one-sided pain and autonomic symptoms.
- A case report describes a 22-year-old male with difficult-to-treat CH who found significant relief using propranolol, a beta-blocker.
- The low dose of propranolol provided effective symptom management without noticeable side effects, suggesting it could be a viable option for those with resistant CH.
Noradrenergic Mechanisms and Circuitry of Hyperkatifeia in Alcohol Use Disorder.
Biol Psychiatry
March 2025
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California. Electronic address:
Article Synopsis
- Hyperkatifeia refers to emotional distress and is recognized as a significant factor contributing to addiction, particularly in the context of alcohol use disorders (AUD).
- Negative life experiences can trigger increased alcohol consumption, leading to the development of AUD, with hyperkatifeia often emerging during withdrawal and promoting relapse.
- The review highlights the role of norepinephrine and its dysfunction in AUD, emphasizing the need for targeted treatments and indicating that certain populations, like women and those with comorbid conditions, may particularly benefit from these therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!